INTEGRATING BIOREACTOR SYSTEM TO SPEED UP TUMOUR INFILTRATING LYMPHOCYTES (TILS) IMMUNOTHERAPY COMMERCIALIZATION

  • A. D. BUDIYATI Doctoral Program for Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Stem Cell and Cancer Institute, Jakarta, Indonesia
  • J. A. PAWITAN Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Stem Cell Medical Technology Integrated Service Unit, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Indonesia, Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine Universitas Indonesia, Indonesia

Abstract

One of the major breakthroughs on adoptive cell transfer (ACT) is autologous T cells transfer that either derived from tumour infiltrating lymphocytes (TILs) or genetically engineered T cells, which express tumour recognizing receptors. Between those two, when the purpose is to treat solid tumours, a more impressive clinical trial result is demonstrated by TIL therapy. The efficacy of TIL therapy is due to its highly personalized approach in generating T cells from the patient’s own tumour tissue. Regardless to its efficacy, TIL therapy in a commercial setting is limited, mainly due to the complexity and costs of cell expansion protocols. This issue has triggered the need to develop effective methods to expand TILs ex vivo, in a safe, efficient, and reproducible manner. In line with this need, there are two main types of bioreactors that have recently been used to generate T cells for ACT, which might suit the requirements for TIL manufacture. Therefore, in this review, we highlighted recent updates on TILs expansion protocol, particularly in autologous settings, as well as the aspect of each bioreactor to be considered before integrating them into TIL manufacturing process.

Keywords: Adoptive cell transfer, Immunotherapy, Tumour infiltrating lymphocytes, Bioreactor, Solid tumour

References

1. Met O, Molgaard K, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy. Semin Immunopathol 2019;41:49-58.
2. Wang X, Riviere I. Clinical manufacturing of CAR T cells: the foundation of a promising therapy. Mol Ther Oncol 2016;3:16015.
3. Raghunathani K, Devi B. Chimeric antigen receptor for chronic lymphocytic leukemia-a review. Asian J Pharm Clin Res 2019;12:62-7.
4. Sulaiman AA, Al-Shamaa ZA, Al-Assadi ME. Evolving role of CAR T-cell in cancer immunotherapy. Int J Curr Pharm Res 2019;11:19-27.
5. Garber K. Pursuit of tumor-infltrating lymphocyte immunotherapy speeds up. Nat Biotechnol 2019;37:969-77.
6. Wickstrom S, Lovgren T. Expansion of tumor-infiltrating lymphocytes from melanoma tumors. Methods Mol Biol 2019;1913:105-18.
7. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy SL, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988;319:1676-80.
8. Dudley ME, Wunderlich JR, Shelton TE, Even J, Steven A. Generation of tumour infiltrating lymphocytes cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332–42.
9. Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. Virchows Archiv 2019;474:449–61.
10. Dillman R, Schiltz P, DePriest C, Barth N, Beutel L, de Leon C, et al. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 2004;19:730-7.
11. Geukes Foppen MH, Donia M, Svane IM, Haanen JBAG. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol 2015;9:1918-35.
12. Mayor P, Starbuck KS, Zsiros E. Adoptive cell transfer using autologous tumour infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 2018;150:361–9.
13. Dudley ME, Rosenberg SA. CD8+enriched “young” tumour infiltrating lymphocytes can mediate the regression of metastatic melanoma. Clin Cancer Res 2010;16:6122-31.
14. Sommerville RP, Dudley ME. Bioreactors get personal. OncoImmunology 2012;1:1435-7.
15. Ready to process WAVE 25 bioreactor. Available from https://www.gelifesciences.com/en/sg/shop/cell-culture-and-fermentation/rocking-bioreactors/systems/readytoprocess-wave-25-rocker-p-05542 [Last accessed on 15 Jan 2020]
16. Bajgain P, Mucharla R, Wilson J, Welch, Anurathapan U, Liang U, et al. Optimizing the production of suspension cells using the G-Rex “M” series. Mol Ther Methods Clin Dev 2014;1:14015.
17. Coeshott C, Vang B, Jones M, Nankervis B. Large scale expansion and characterization of CD3+T-cells in the quantum cell expansion system. J Transl Med 2019;17:258.
18. Malone CC, Schiltz PM, Mackintosh AD, Beutel LD, Heinemann FS, Dillman RO. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biother Radiopharm 2001;16:381-90.
19. Schmid J, Schwarz S, Staude RM, Sudhop S, Schaumann HC, Schieker M, et al. A perfusion bioreactor system for cell seeding and oxygen-controlled cultivation of three-dimensional cell cultures. Tissue Eng 2018;24:585-95.
20. Bausch M, Schultheiss C, Sieck JB. Recommendations for comparison of productivity between fed-batch and perfusion processes. Biotechnol J 2019;14:e1700721.
21. Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J Transl Med 2012;10:69.
22. Donia M, Larsen SM, Met O, Svane IM. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the wave bioreactor. Cytotherapy 2014;16:1117-20.
Statistics
78 Views | 126 Downloads
Citatons
How to Cite
BUDIYATI, A. D., & PAWITAN, J. A. (2020). INTEGRATING BIOREACTOR SYSTEM TO SPEED UP TUMOUR INFILTRATING LYMPHOCYTES (TILS) IMMUNOTHERAPY COMMERCIALIZATION. International Journal of Applied Pharmaceutics, 12(4), 34-38. https://doi.org/10.22159/ijap.2020v12i4.37244
Section
Review Article(s)